Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
about
Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegenerationCorrelating AMPA Receptor Activation and Cleft Closure across Subunits: Crystal Structures of the GluR4 Ligand-Binding Domain in Complex with Full and Partial Agonists †High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma CellsCellular host responses to gliomasGlioblastoma cells express functional cell membrane receptors activated by daily used medical drugs.Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer modelA role for intracellular zinc in glioma alteration of neuronal chloride equilibrium.Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB.Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.Brain to blood glutamate scavenging as a novel therapeutic modality: a reviewIn vivo magnetic resonance imaging of sodium and diffusion in rat glioma at 21.1 T.Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration.Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo.Autocrine glutamate signaling promotes glioma cell invasion.Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapy.Overview of Glutamatergic Dysregulation in Central Pathologies.The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas.Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.Ionotropic glutamate receptors & CNS disorders.Inhibition of cystine uptake disrupts the growth of primary brain tumors.Functional role of CLIC1 ion channel in glioblastoma-derived stem/progenitor cells.Cell migration in the normal and pathological postnatal mammalian brain.A by-product of glutathione production in cancer cells may cause disruption in bone metabolic processes.Glutamate and the biology of gliomas.Vacquinol-1 inducible cell death in glioblastoma multiforme is counter regulated by TRPM7 activity induced by exogenous ATP.Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma.Adenovirus-mediated expression of BmK CT suppresses growth and invasion of rat C6 glioma cells.Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.Mislocalization of the exitatory amino-acid transporters (EAATs) in human astrocytoma and non-astrocytoma cancer cells: effect of the cell confluence.Water permeability through aquaporin-4 is regulated by protein kinase C and becomes rate-limiting for glioma invasion.Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression.Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells.Serum-dependence of AMPA receptor-mediated proliferation in glioma cells.Combined treatment of fasudil and glutamate decreased the viability of human glioblastoma cells by excitotoxicity through NMDAR in vitroTransient increase in neuronal chloride concentration by neuroactive aminoacids released from glioma cells.Molecular structure and function of big calcium-activated potassium channels in skeletal muscle: pharmacological perspectives.Developmentally regulated signaling pathways in glioma invasion.Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy.
P2860
Q24676501-A58B3069-55B4-46A2-BD8D-28D1B9854731Q27653239-30131974-1A65-4BA1-97AA-3E6BA23D0494Q28547125-629DAF55-494C-4D8A-9676-805B29B9BB96Q28730429-2832A384-516B-47BF-9620-CB6434B17D56Q33471536-C65051F2-1242-4FA6-8C68-368F2776C5FEQ34439601-4A7184CC-82D2-46FA-93F5-3F20CFF04C6FQ34541640-4B3D46B7-FCFF-4598-B53D-7F1B9DBF9016Q34543666-6702B3B6-5901-4621-8429-5BDC1D2DF847Q34749647-067AD06E-E7A9-48A8-92D4-A6B6FF33A868Q35067815-78297463-474A-44D9-9F6F-FFC8296CEE4CQ35241461-CC9B25B3-AE48-435A-96E2-597A70C5FBB9Q35353492-D021483D-A054-46A1-997B-448148CB17C2Q35640113-7A42A565-0C07-405D-9FEC-BA2E2E5419F3Q35800481-15E81ACF-89EF-45ED-91EE-6A8A72BB1D3EQ36098125-0FB38294-F1D9-480C-8F5C-64D296CE18E0Q36393422-F3DE8BBC-7D96-4108-B74A-E9033CA09AF7Q36409596-2700D85A-E9A4-4E8D-91F2-BF199AA5A549Q36485266-832A93F6-120C-42DA-937A-003236A433FEQ36603152-1531E218-F846-455B-A538-F1B4E8D2C9C1Q37121338-8D5904D8-C4EC-47F2-A44F-B084AC743BC5Q37143580-BEDBCD34-14D4-4DDE-9884-137BFCB62A59Q37189377-32374DA0-48CF-4AAE-BA6A-50F6E761A98CQ37281605-71F3B004-B7AF-4993-8C81-30DBEBC6CDC2Q37476131-6467C395-1E15-404F-B266-160498545F82Q37731331-CB14445A-0AC9-4A38-8ABF-09C5360A050CQ37824652-5CC133A7-73CF-44F3-B1EE-3A2E71DBF04EQ38707656-1D579307-D6FB-4E9E-B927-1F2ACE4A4A91Q39116562-4A21C474-89A5-4B5E-8E02-A8103EFB21ACQ39188207-1EF1191B-84B1-40C0-8F15-800AE0F518D6Q39384950-68725F21-22F0-43F1-A22F-C9E4FAF47660Q39403123-D836272B-57EB-4C13-BA3B-66D1F7F473A2Q39798369-8945545D-5AAC-431F-8061-15CE05BB5738Q39914990-83CE8ED6-E1ED-4722-80B2-9AF386927148Q40008856-4FBF2121-F6BB-4063-B2E5-97DB39088E9AQ40284526-186D4F76-05B3-45BB-B43C-5903D92B0098Q41571486-7D6E77DD-A405-49FE-876F-101BFC8AE954Q42351685-4E8C09C2-4E04-45E7-81A5-4A268FB41072Q46202283-085D2FB7-F5BA-4873-A51D-F53B9FCDDFB7Q48148598-8579B113-DBE6-4B13-951B-9BA916EB604FQ48892545-6BA91B2B-C649-416D-BB53-73846A5A6EFE
P2860
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
@ast
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
@en
type
label
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
@ast
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
@en
prefLabel
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
@ast
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage.
@en
P1476
Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage
@en
P2093
Harald Sontheimer
P304
P356
10.1016/J.TINS.2003.08.007
P577
2003-10-01T00:00:00Z